AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05515796
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: q3w Trastuzumab (6 mg/kg following an initial loading dose of 8 mg/kg) on day 1 of each cycle
Trial: NCT06119529
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT05490082
Drug: Mirabegron, Propevirine, Solifenacin
DrugBank: Solifenacin (DB01591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Efficacy comparison
Trial: NCT05717335
Drug: TachoSil
RxNorm normalized name: TachoSil
DrugBank: Fibrinogen human (DB09222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placement of TachoSil over the ventricular entry point in patients with periventricular lesions in order to avoid complications related to the ventricular entry.
Trial: NCT06094140
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab will be supplied by AstraZeneca as a 500 mg vial concentrate for solution for infusion. The solution contains 50 mg/mL durvalumab, 26 mM histidine/histidine-hydrochloride, 275 mM trehalose dihydrate, and 0.02% weight/volume (w/v) polysorbate 80; it has a pH of 6.0 and density of 1.054 g/mL. The label-claim volume is 10 mL.~Durvalumab is a sterile, clear to opalescent, colorless to slightly yellow solution, free from visible particles.~Investigational product vials are stored at 2°C to 8°C (36°F to 46°F) and must not be frozen. Investigational product must be kept in original packaging until use to prevent prolonged light exposure.
Trial: NCT06094140
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 85mg/m2 intravenously on day 1
Trial: NCT06094140
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 150mg/m2 intravenously on day 1
Trial: NCT06094140
Drug: Pegylated G-CSF
RxNorm normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 6mg by subcutaneous injection to be given on day 3 of each cycle.
Trial: NCT05654649
Drug: 0.9%sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients received 5 ml of IV normal saline as a placebo just before spinal anesthesia
Trial: NCT05654649
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients received IV dexamethasone 8 mg in 5ml normal saline 0,9%, just before spinal anesthesia.
Trial: NCT06383884
Drug: Patritumab Deruxtecan
RxNorm normalized name: patritumab deruxtecan
DrugBank: Patritumab (DB12090)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patritumab deruxtecan will be administered as an IV infusion Q3W on Day 1 of each 21-day cycle as a fixed dose regimen of 5.6 mg/kg Q3W.
Trial: NCT05469490
Drug: navoximod
RxNorm normalized name: Navoximod
DrugBank: Navoximod (DB15439)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A small molecule inhibitor with potent inhibition of IDO1 enzymatic activity as shown both in vitro and in vivo. As the main function of IDO1 is the regulation of acquired immune tolerance, and its expression in tumor- and dendritic cells in tumor draining lymph nodes negatively correlates with cancer prognosis and survival, navoximod-mediated IDO1 inhibition may restore immune reactivity towards tumors.
Trial: NCT05469490
Drug: NLG802 (indoximod Prodrug)
RxNorm normalized name: Indoximod
DrugBank: Indoximod (DB12827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An anti-tumor immunomodulator with the active ingredient of 1-methyl-D-tryptophan (NSC- 721782, 1-MT), which is an inhibitor of the indoleamine 2,3-dioxygenase (IDO) pathway that increases the bioavailability of indoximod by leveraging existing mechanisms of absorption, increasing the exposure of indoximod.
Trial: NCT01714089
Drug: Interferon beta 1a
RxNorm normalized name: Interferon beta 1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05096715
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous Infusion
Trial: NCT05096715
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous Infusion
Trial: NCT05550337
Drug: Trifarotene 0.005 % Topical Cream
RxNorm normalized name: trifarotene 0.005 % Topical Cream
DrugBank: Trifarotene (DB12808)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cream
Trial: NCT04091243
Drug: Romosozumab
RxNorm normalized name: ROMOSOZUMAB
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Experimental drug for the treatment of glucocorticoid induced osteoporosis
Trial: NCT04762186
Drug: human SARS-CoV 2 specific T lymphocytes
RxNorm normalized name: SARS-COV
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In dose level one, SARS-CoV-2 infected patients will receive 1,000 viable human SARS CoV-2 specific T lymphocytes per kg BW.~In dose level two SARS-CoV-2 infected patients will receive 5,000 viable human SARS CoV-2 specific T lymphocytes per kg BW.~In parallel, all patients will receive the current SoC treatment for COVID-19.
Trial: NCT05719961
Drug: Insulin Aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Part I: A single dose of 0.2U/kg is administered.
Trial: NCT05719961
Drug: Insulin Aspart 30 Injection
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Part II: A single dosewas administered
Trial: NCT05604417
Drug: TAZEMETOSTAT
RxNorm normalized name: tazemetostat
DrugBank: Tazemetostat (DB12887)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dosage and treatment timings per protocol
Trial: NCT05604417
Drug: Zandelisib
RxNorm normalized name: Zandelisib
DrugBank: Zandelisib (DB18245)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage and treatment timings per protocol
Trial: NCT06613776
Drug: Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 capsules of amoxicillin 500mg, 2 grams in total, one hour before surgery
Trial: NCT06697522
Drug: Atropine Sulfate
RxNorm normalized name: Atropine Sulfate
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: low concentration atropine (0.01%)
Trial: NCT05137860
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Combination of Bortezomib with Standard Chemotherapy scheme for acute lymphoblastic patients in relapse.
Trial: NCT06711679
Drug: Low-dose ropivacaine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5 ml/Kg ropivacaine
Trial: NCT06711679
Drug: Medium-dose of ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1ml/Kg ropivacaine
Trial: NCT06711679
Drug: High-dose ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.5 ml/Kg ropivacaine
Trial: NCT04680910
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Targeted propofol infusion in TRD patients will induce sedation with maximal expression of EEG slow waves and minimal burst suppression.
Trial: NCT05805098
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Starting on day 1, venetoclax will be dose escalated to a target dose of 600 mg in the following manner: 100 mg on day 1, 200 mg on day 2 and 400 mg on day 3. The patient then continues to take the 400mg dose for the remainder of the 28 day cycle. Each dose of venetoclax will be self-administered with approximately 240 mL of water within 30 minutes after the completion of a meal, preferably breakfast. The dose should be administered at the same time each day.
Trial: NCT05805098
Drug: Homoharringtonine
RxNorm normalized name: Homoharringtonine
DrugBank: Omacetaxine mepesuccinate (DB04865)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On day 1, homoharringtonine 1 mg/m2 IV will be given, and will continue for 5 days.
Trial: NCT05805098
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: On day 1, cytarabine 100 mg/m2 IV will be given, and will continue for 5 days.
Trial: NCT05881811
Drug: HSK16149，probenecid, cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40mg HSK16149 single dose, fasted; 500mg probenecid QID from D1\~D4 200mg cimetidine QID from D1\~D4
Trial: NCT05474664
Drug: Camostat mesylate
RxNorm normalized name: camostat mesylate
DrugBank: Camostat (DB13729)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. 4\~12 years old: Camostate mesylate 100 mg, 2 times a day~2. greater than 13 years old: Camostate mesylate 100 mg, 3 times a day
Trial: NCT05924893
Drug: Naltrexone Hydrochloride
RxNorm normalized name: Naltrexone Hydrochloride
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: naltrexone film
Trial: NCT05290116
Drug: HAIC Combined with Tislelizumab and Apatinib
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatic Arterial Infusion Chemotherapy: FOLFOX6 regimen was infused with chemotherapy drugs: oxaliplatin 130 mg/m2 infusion for 2 hours, folinate calcium 400 mg/m2 infusion for 2 hours, 5-fluorouracil 400 mg/m2 arterial infusion for 10 minutes, 5-fluorouracil 1200 mg/m2 infusion for 23 hours. Every 3 weeks, no more than 4 cycles of HAIC treatment.~Tislelizumab and Apatinib treatment: start at 0-3 days after the end of hepatic arterial infusion chemotherapy: Tislelizumab 200 mg, ivdrip, Q3W; Apatinib 250 mg, po, QD.
Trial: NCT05924893
Drug: Carboxy methyl cellulose
RxNorm normalized name: Methyl cellulose
DrugBank: Carboxymethylcellulose (DB11059)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboxy methyl cellulose drops
Trial: NCT04800627
Drug: Pevonedistat
RxNorm normalized name: Pevonedistat
DrugBank: Pevonedistat (DB11759)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT06166108
Drug: transversus abdominis plane (TAP) block in Abdominal hysterectomy
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparative evaluation of magnesium sulphate versus dexamethasone as an adjuvant to bupivacaine in ultrasound guided transversus abdominis plane block for Abdominal hysterectomy as postoperative analgesia.
Trial: NCT04487925
Drug: A single Gonadotropin-Releasing Hormone (GnRH) antagonist corifollitropin alfa (CFA) stimulation
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: CFA will be administered in combination with Follitropin beta.
Trial: NCT04487925
Drug: Up to three modified natural cycles with Follitropin beta.
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Follitropin beta in a low dose will be given.
Trial: NCT04880213
Drug: M5049
RxNorm normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive single oral dose of film-coated tablet M5049 at low dose on Day 1 under fasted condition.
Trial: NCT04880213
Drug: M5049
RxNorm normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive single oral dose of film-coated tablet M5049 at medium dose on Day 1 under fasted condition.
Trial: NCT04677504
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.
Trial: NCT04677504
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab will be administered at a dose of 15 mg/kg intravenously on Day 1 of each 21-day cycle after atezolizumab.
Trial: NCT04677504
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin will be administered intravenously at a dose of 25 mg/m\^2 on Days 1 and 8 of each 21-day cycle for Cycles 1-8.
Trial: NCT04677504
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine will be administered intravenously at a dose of 1000 mg/m\^2 on Days 1 and 8 of each 21-day cycle for Cycles 1-8.
Trial: NCT04880213
Drug: M5049
RxNorm normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive single oral dose of film-coated tablet M5049 at high dose on Day 1 under fasted condition.
Trial: NCT05254249
Drug: Lactobacillus Plantarum IS-10506
DrugBank: Lactobacillus plantarum (DB11360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indonesian original probiotic, given in capsule form with a dose of 2 x 1010 CFU
Trial: NCT05288543
Drug: IPG7236- Multiple ascending dose
RxNorm normalized name: IODINE 1 kg in 1 kg TOPICAL LIQUID [ASCEND]
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive IPG7236 tablets orally once daily for 10 days from Day1 to Day 10 in a fasted state
Trial: NCT05528848
Drug: Carfentanil, C-11
RxNorm normalized name: Carfentanil, C-11
DrugBank: Carfentanil, C-11 (DB15360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational radiotracer to be injected by IV as s a bolus during both study PET/CT scans.
Trial: NCT05528848
Drug: Naloxone
RxNorm normalized name: Naloxone
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-selective opioid antagonist injected by IV parenterally during the second study PET/CT scan only.
Trial: NCT05528848
Drug: Loperamide Hydrochloride
RxNorm normalized name: Loperamide Hydrochloride
DrugBank: Loperamide (DB00836)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loperamide is an FDA- approved, over-the-counter drug for the control and symptomatic relief of acute or chronic diarrhea given orally prior to the optional HC third PET/CT scan only.
Trial: NCT06121570
Drug: Epirubicin
RxNorm normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epirubicin will be administered at 100 mg/m\^2 IV on Day 1 of Cycles 1-2 of the neoadjuvant chemotherapy of the study.
Trial: NCT06121570
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine will be administered at 30 mg/m\^2 IV daily for three days. Fludarabine will be initiated five days prior to the anticipated LNL transfer, and the precise timing will depend on the rate of in vitro LNL growth.
Trial: NCT06121570
Drug: Nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab-paclitaxel will be administered at 260 mg/m\^2 IV on Day 1 of Cycles 3-6 of the neoadjuvant chemotherapy of the study.
Trial: NCT06107920
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diverting stoma- neoadjuvant chemotherapy - colectomy - +/- adjuvant chemotherapy
Trial: NCT01775098
Drug: allopurinol
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No arms will not be change as the study as been closed.
Trial: NCT05474846
Drug: Methylphenidate
RxNorm normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given by PO
Trial: NCT06351904
Drug: RAG-01
RxNorm normalized name: RAG-17
DrugBank: RAG-17 (DB18503)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAG-01 is a therapeutic small activating RNA (saRNA).
Trial: NCT04903002
Drug: 24-IU oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will self-administer a 2-week course of 24-IU intranasal oxytocin \[4-IU per puff (12-IU delivered to each nostril); Syntocinon, Novartis, Switzerland\], twice per day (once in the morning and once in the evening).
Trial: NCT04903002
Drug: 48-IU oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will self-administer a 2-week course of 48-IU intranasal oxytocin \[4-IU per puff (24-IU delivered to each nostril); Syntocinon, Novartis, Switzerland\], twice per day (once in the morning and once in the evening).
Trial: NCT04607252
Drug: Metformin plus Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: metformin 1500mg, per day, oral; megestrol acetate 160mg per day, oral
Trial: NCT04607252
Drug: Megestrol Acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol acetate (DB00351)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: megestrol acetate 160mg per day, oral
Trial: NCT06408246
Drug: Guanfacine
RxNorm normalized name: Guanfacine
DrugBank: Guanfacine (DB01018)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Guanfacine immediate release is an established and safe FDA-approved treatment that acts directly by stimulating α2A adrenoceptors.
Trial: NCT06408246
Drug: Sertraline
RxNorm normalized name: Sertraline
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sertraline is a well-tolerated FDA-approved antidepressant that is among the most widely prescribed medications for depression.
Trial: NCT06517199
Drug: Olanzapine 2.5 MG
RxNorm normalized name: olanzapine 2.5 MG
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: olanzapine 2.5 mg/day for 28 days
Trial: NCT06517199
Drug: Olanzapine 5 MG
RxNorm normalized name: olanzapine 5 MG
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: olanzapine 5 mg/day for 28 days
Trial: NCT05571813
Drug: CKD-341
RxNorm normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of 1tablets under fasting condition
Trial: NCT06061484
Drug: Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard weight-based dosing per Ehtiopian national guidelines
Trial: NCT06284473
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketamine is an N-methyl-D aspartate receptor agonist
Trial: NCT05060471
Drug: Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four cycles of neoadjuvant PD-1 antibody toripalimab combined with docetaxol and cisplatin, followed by radiotherapy and two cycles of concurrent toripalimab.
Trial: NCT04739423
Drug: clenbuterol (CST-103), nadolol (CST-107), matching placebo
DrugBank: Nadolol (DB01203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: clenbuterol (CST-103) and matching placebo orange capsules; nadolol (CST-107) and matching placebo white capsules
Trial: NCT00000730
Drug: Trimetrexate glucuronate
RxNorm normalized name: Trimetrexate Glucuronate
DrugBank: Trimetrexate (DB01157)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000730
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000730
Drug: Pentamidine isethionate
RxNorm normalized name: Pentamidine Isethionate
DrugBank: Pentamidine (DB00738)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000730
Drug: Sulfamethoxazole-Trimethoprim
RxNorm normalized name: sulfamethoxazole-trimethoprim
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05117034
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraoperative intravenous administration of 0.08 mg/kg morphine at dura closure.
Trial: NCT04724226
Drug: Camrelizumab; Apatinib
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cryoablation~Drug: Camrelizumab and Apatinib Camrelizumab (200mg), iv, Q3W; Apatinib (250mg), po, QD
Trial: NCT05773989
Drug: CYP2C19 genotype guided P2Y12 monotherapy
RxNorm normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients without a LOF-allel will receive clopidogrel monotherapy (tablet of 75mg once daily) for 6 months. Patients with a LOF-allel will receive ticagrelor (tablet of 90mg twice daily) or prasugrel (tablet of 10mg once daily) for 6 months.
Trial: NCT05773989
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Standard DAPT according to current guidelines with clopidogrel (tablet of 75mg once daily) for 6 months and acetylsalicylic acid (tablet 80mg one daily) for 6 months.
Trial: NCT05052554
Drug: QR-504a
RxNorm normalized name: mannitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravitreal (IVT) injection
Trial: NCT03702036
Drug: molibresib
RxNorm normalized name: Molibresib
DrugBank: Molibresib (DB16239)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: molibresib 20 mg will be supplied for compassionate use for the identified individual subject.
Trial: NCT05181215
Drug: Monomethyl Fumarate 190 Mg
RxNorm normalized name: Monomethyl fumarate
DrugBank: Monomethyl fumarate (DB14219)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x oral 95 mg capsules, delayed-release
Trial: NCT05826574
Drug: Brensocatib
RxNorm normalized name: Brensocatib
DrugBank: Brensocatib (DB15638)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets.